69 results
DEF 14A
NAMS
NewAmsterdam Pharma Company NV
9 May 24
Definitive proxy
4:15pm
to participate in our equity incentive plans, including the Company’s long-term incentive plan (the “LTIP”), and other employee benefits and insurance … supplementary long-term incentive plan (the “Supplementary LTIP”), under which we may grant options, restricted shares, restricted share units, share appreciation
8-K
EX-99.1
NAMS
NewAmsterdam Pharma Company NV
9 May 24
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
8:00am
Property, plant and equipment, net
Operating right of use asset
Intangible assets
Long term prepaid expenses
Total assets
Liabilities and Shareholders
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
assets
Property, plant and equipment, net
Operating right of use asset
Intangible assets
Long term prepaid expenses
Total assets
Liabilities … :
The Company’s Long-Term Incentive Plan (the “Plan”);
The Company’s Supplementary Long-Term Incentive Plan (the “Supplementary Plan”);
The Company’s
PRE 14A
NAMS
NewAmsterdam Pharma Company NV
29 Apr 24
Preliminary proxy
5:00pm
, including the Company’s long-term incentive plan (the “LTIP”), and other employee benefits and insurance programs generally made available to our full-time … applicable in the event of a change of control.
Supplementary LTIP
We have also established our supplementary long-term incentive plan (the “Supplementary
424B3
NAMS
NewAmsterdam Pharma Company NV
19 Apr 24
Prospectus supplement
4:21pm
;
116,971 Ordinary Shares reserved for issuance pursuant to future awards under the Company’s Long-Term Incentive Plan;
63,922 Ordinary Shares reserved … to future awards under the Company’s Supplementary Long-Term Incentive Plan; and
1,886,137 Ordinary Shares issuable upon the achievement of a certain
POS AM
djwat laot5j4
12 Apr 24
Prospectus update (post-effective amendment)
4:15pm
424B3
h1iv84unfz40buib jf
12 Mar 24
Prospectus supplement
4:18pm
POS AM
u58pbgb
28 Feb 24
Prospectus update (post-effective amendment)
5:01pm
8-K
EX-99.1
lnx08nyi5y7ds
28 Feb 24
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
8:11am
10-K
EX-10.4
yfgd75n3qkw51w
28 Feb 24
Annual report
8:00am
10-K
EX-10.9
b7bpmcg2is6ggyy3h
28 Feb 24
Annual report
8:00am
10-K
vds05yvv
28 Feb 24
Annual report
8:00am
10-K
EX-10.8
eea00n02 5fpybh
28 Feb 24
Annual report
8:00am
10-K
EX-10.7
tdq2txkh
28 Feb 24
Annual report
8:00am
10-K
EX-10.10
sfuff6n
28 Feb 24
Annual report
8:00am
8-K
EX-1.1
07bvle
15 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
4:18pm
424B5
a9wyde8hpg5v 34jjw
15 Feb 24
Prospectus supplement for primary offering
4:15pm
424B5
4t4dv 32y
13 Feb 24
Prospectus supplement for primary offering
5:19pm
8-K
EX-99.1
3flo5zxn4 88
22 Jan 24
Regulation FD Disclosure
8:01am
8-K
fco2h0qrxaoz9
8 Jan 24
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
8:21am